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Abstract
Current echocardiographic data reporting the impact of concomitant mitral regurgitation (MR) on outcome in patients who 
undergo transcatheter aortic valve replacement (TAVR) are conlicting. Using cardiovascular magnetic resonance (CMR) 
imaging, this study aimed to assess the impact of MR severity on cardiac reverse remodeling and patient outcome. 85 patients 
undergoing TAVR with CMR pre- and 6 m post-TAVR were evaluated. The CMR protocol included cines for left (LV) and 
right ventricular (RV) volumes, low assessment, and myocardial scar assessment by late gadolinium enhancement (LGE). 
Patients were dichotomised according to CMR severity of MR fraction at baseline (‘non-signiicant’ vs ‘signiicant’) and 
followed up for a median duration of 3 years. Forty-two (49%) patients had ‘signiicant MR’ at baseline; they had similar 
LV and RV size and function compared to the ‘non-signiicant MR’ group but had greater LV mass at baseline. In those with 
signiicant MR at baseline, 77% (n = 32) had a reduction in MR post-TAVR, moving them into the ‘non-signiicant’ category 
at 6-months, with an overall reduction in MR fraction from 34 to 17% (p < 0.001). Improvement in MR was not associated 
with more favourable cardiac reverse remodeling when compared with the ‘non-improvers’. Signiicant MR at baseline was 
not associated with increased mortality at follow-up. Signiicant MR is common in patients undergoing TAVR and improves 
in the majority post-procedure. Improvement in MR was not associated with more favourable LV reverse remodeling and 
baseline MR severity was not associated with mortality.
Keywords Mitral regurgitation · Mitral insuiciency · Transcatheter aortic valve replacement · Cardiovascular magnetic 
resonance · Late gadolinium enhancement
Abbreviations
AS  Aortic stenosis
AVA  Aortic valve area
CMR  Cardiovascular magnetic resonance
FOV  Field of view
LGE  Late gadolinium enhancement
LV  Left ventricular
LVEDP  LV end-diastolic pressure
MR  Mitral regurgitation
PG  Pressure gradient
RV  Right ventricular
SD  Standard deviation
TAVR  Transcatheter aortic valve replacement
VENC  Velocity encoded
Introduction
Transcatheter aortic valve replacement (TAVR) has been 
shown to reduce mortality and improve patient symptoms 
and quality of life [1–3], and is an alternative to surgery in 
intermediate and high-risk patients with severe aortic steno-
sis (AS) [4]. Whilst moderate or severe mitral regurgitation 
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(MR) is seen in up to 48% of patients undergoing TAVR, 
it is often left untreated [5–7]. Current literature report-
ing the impact of concomitant MR on outcome in patients 
who undergo TAVR are conlicting and are mainly based 
on echocardiographic data; which can be limited by poor 
acoustic windows, eccentric jets and geometric assumptions 
[8]. Cardiovascular magnetic resonance (CMR) imaging is 
able to quantify MR with high accuracy and reproducibil-
ity using a combination of left ventricular (LV) volumetric 
measurements and aortic low quantiication [9–11]. Tissue 
characterization is a further unique strength of CMR, ofer-
ing non-invasive detection of myocardial ibrosis [12]. In a 
TAVR population however, quantitative serial assessment of 
MR by CMR has never been speciically studied, despite its 
objectiveness, reproducibility and accuracy.
The aims of this study were to (1) to quantitate the change 
in MR severity at 6-months post-TAVR using CMR, (2) 
identify determinants of improvement in MR and its asso-
ciation with LV reverse remodeling, (3) assess the clini-
cal impact of MR on the outcomes of patients undergoing 
TAVR.
Methods
Study design and population
In this prospective study, 109 patients with severe AS under-
going TAVR between April 2009 and September 2015 at 
a single tertiary centre (Leeds General Inirmary, Leeds, 
UK) were evaluated. Severe AS was deined as an echo-
cardiographically derived aortic valve area of ≤ 1.0 cm2, 
peak aortic velocity of > 4 m/s or mean pressure gradi-
ent of > 40 mmHg. Decision for TAVR intervention was 
taken by a multidisciplinary heart team in accordance with 
international guidance. Exclusion criteria included any con-
traindications to CMR. Baseline clinical, demographic and 
echocardiographic data were recorded for all patients. CMR 
scans were performed at baseline and 6-months post-TAVR.
All patients were followed up for a median duration of 
3 years and their long-term outcomes were evaluated. Mor-
tality data were obtained from the Oice of National Statis-
tics, UK. All patients provided written informed consent. 
The study was approved by the National Research Ethics 
Service (08/H1307/106) and complied with the Declaration 
of Helsinki.
TAVR
Patients underwent a standard work-up for TAVR which 
included transoesophageal echocardiography and invasive 
coronary angiography, with the addition of cardiac com-
puted tomography after 2014. Coronary revascularisation 
was only performed in those with critical proximal lesions 
or symptomatic angina. TAVR was performed under gen-
eral or local anaesthetic using the self-expanding Medtronic 
CoreValve (Medtronic Inc, Minneapolis, MIN) or the 
mechanically expanded Boston Lotus valve (Boston Scien-
tiic Corporation, Natick, MA) via the femoral or subcla-
vian route by two experienced, high-volume operators. All 
patients received heparin to maintain an activated clotting 
time > 250 s and were treated with dual antiplatelet therapy 
(aspirin and clopidogrel) for 3–6 months after the procedure.
CMR protocol
Details of the CMR pulse sequence have been previously 
described [13]. Briely, identical baseline preoperative and 
6-month postoperative scans were performed on a 1.5T 
MRI system (Intera, Philips Healthcare, Best, Netherlands 
or Avanto, Siemens Medical Systems, Erlangen, Germany); 
same scanner vendor used at baseline and 6-months. Multi-
slice, multi-phase cine imaging was performed using a 
standard steady-state free precession pulse sequence in 
the short axis (repetition time (TR) 3 ms, echo time (TE) 
1.7 ms, lip angle 60°, SENSE factor 2, 8 mm thickness, 
0 mm gap, 30 phases, matrix 192 × 192, typical ield of view 
(FOV) 340 mm) to cover the entire left and right ventricle. 
Through-plane velocity encoded (VENC) phase contrast 
imaging was performed at the aortic sinotubular junction 
(VENC 250–500 cm/s, retrospective gating, slice thickness 
6 mm, 40 phases, FOV 340 mm) or just above the valve 
prosthesis post-replacement. VENC was typically set at 
400–500 cm/s on the baseline scan and 250 cm/s post-pro-
cedure. If aliasing occurred at the pre-set VENC, sequential 
phase contrast imaging was performed at increasing VENC 
settings until the aliasing artefact had disappeared.
Late gadolinium enhancement (LGE) imaging (10–12 
short axis slices, 10 mm thickness, matrix 240 × 240, typi-
cal FOV 340 mm) was performed following a Look-Locker 
sequence (inversion time scout), 10 min after the administra-
tion of 0.2 mmol/kg of gadoteric acid (Dotarem, Guerbet, 
Villepinte). Four chamber, two chamber and left ventricular 
outlow tract (LVOT) views were also obtained as standard. 
Cross cuts and phase swap imaging were used where neces-
sary for further clariication of the presence/absence of LGE.
CMR analysis
CMR analysis was performed by two experienced CMR 
operators (LED, PGC) blinded to clinical details, using 
dedicated computer software  (CVI42, Circle Cardiovascular 
Imaging, Calgary, Alberta, Canada). LV endocardial and 
epicardial borders were manually contoured (with trabecu-
lation and papillary muscles excluded) at end-diastole and 
end-systole to allow the calculation of ventricular volumes 
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(summation of discs methodology) and LV mass [epicardial 
volume − endocardial volume multiplied by myocardial den-
sity (1.05 g/cm3)]; values were indexed to body surface area. 
Left atrial volume was calculated using the formula:
where  A2Ch and  A4Ch refer to the left atrial area in the two-
chamber and four-chamber views respectively, and L is the 
shorter of the two left atrial length measurements. Aortic 
low was quantiied using cross-sectional phase contrast 
images with contouring of the aortic lumen to provide aor-
tic forward low data. MR fraction (%) was quantiied using 
the equation:
‘Signiicant MR’ was deined as MR fraction > 25% and 
‘non-signiicant MR’ was deined as MR fraction ≤ 25% 
[10]. For the purpose of this study, ‘signiicant MR’ repre-
sented moderate-severe/severe categories and ‘non-signii-
cant MR’ comprised categories of trivial/mild/moderate as 
per CMR classiication. Changes in the MR severity were 
assessed between the baseline and 6-month post-procedure 
scans. Those with a reduction in MR severity grade from 
‘signiicant’ to ‘non-signiicant’ category were classiied 
as ‘improvers’, and those without (i.e. MR worsened or 
unchanged) were labelled as ‘non-improvers’.
LGE images were reviewed for the presence or absence of 
hyper-enhancement, which was then classiied as either non-
infarct pattern (myocardial ibrosis), infarct pattern, or mixed 
pattern. The number and location of segments containing 
LGE were classiied according to the American Heart Asso-
ciation (AHA) 17-segment model. Myocardial ibrosis was 
deined as a region of LGE with signal enhancement > 5 SD 
of the signal intensity of non-enhanced myocardium.
Statistical analysis
All statistical analysis was performed using the SPSS V.21.0 
(IBM Corp., New York, USA). Continuous variables are 
expressed as mean ± SD or median (interquartile range, IQR) 
in cases of skewed distributions. Categorical variables are 
expressed as frequencies and percentages. Data were tested 
for normality using the Shapiro–Wilks test. For normally 
distributed continuous data, two-tailed unpaired Student’s t 
tests were used for comparisons between groups, and paired 
Students t tests were used for intra-group comparisons. For 
non-normally distributed data, Mann–Whitney U-test was 
used. The Chi-Squared test was used for comparing categori-
cal variables.
In order to assess the correlation between dependent and 
independent variables, Pearson’s correlation coeicients 
8 (A2
Ch
)(A4
Ch
)
3πL
LV stroke volume − aortic forward flow volume
LV stroke volume
× 100
were used. Two-sided P values < 0.05 were considered sta-
tistically signiicant. Univariate analysis was used to deter-
mine predictive factors for MR improvement. Variables 
with a univariate p < 0.1 were entered into multi-variable 
regression analysis. Cumulative survival was analyzed with 
Kaplan–Meier methodology and log-rank test.
Results
Patients and baseline characteristics
From 109 patients with a baseline scan, those with a perma-
nent pacemaker (n = 8), severe aortic regurgitation (n = 5) 
or who had an incomplete scan (n = 1), were excluded from 
analysis. Eight patients declined follow up and 2 patients 
died prior to their 6 month scan. 85 patients with paired 
CMR scans (55% male gender, mean age 80 ± 7 years) who 
underwent TAVR for severe AS were included in the inal 
data analysis. Basic demographics and clinical data can be 
seen in Table 1.
In total, 42/85 (49%) patients were classiied as having 
‘signiicant MR’, and 43/85 (51%) as ‘non-signiicant MR’. 
Those with ‘signiicant’ MR had a mitral regurgitant volume 
of 34.5 ± 9.9 ml and a regurgitant fraction of 34.2 ± 5.5%. 
Comparatively, those with ‘signiicant’ MR had a greater 
echocardiographically measured aortic peak forward 
low velocity (4.8 ± 0.47 m/s vs 4.6 ± 0.51 m/s, p = 0.02), 
although mean pressure gradient and aortic valve area did 
not difer signiicantly. The ‘signiicant MR’ group (n = 42) 
had similar LV and right ventricular (RV) cavity size and 
function but had greater LV mass at baseline compared 
to the ‘non-signiicant MR’ group (Table 2). Those with 
signiicant MR also had more aortic regurgitation (aortic 
regurgitant fraction 13.3 ± 6.3% vs 9.5 ± 8.4%, p = 0.008) by 
CMR. The presence of LGE was not statistically diferent 
between groups [‘signiicant’ 21.4% (n = 9) vs ‘non-signii-
cant’ 34.8% (n = 15), p = 0.188].
Cardiac reverse remodeling following TAVR
Following TAVR, all patients sustained a signiicant decrease 
in their peak aortic valve gradient from 41 ± 16 mmHg to 
18 ± 10 mmHg (p < 0.001) by CMR. At 6 months, com-
pared to baseline, there were signiicant reductions in LV 
end-diastolic volumes (p < 0.001), LV end-systolic volumes 
(p = 0.006), and LV mass (p < 0.001) (Table 3). Global LV 
and RV ejection fractions however did not change. In addi-
tion, left atrial volumes signiicantly reduced post-TAVR 
intervention (Table 3).
The ‘significant’ MR group had a greater degree of 
reduction in both MR regurgitant volumes (− 19 ± 14 ml 
vs 1 ± 13 ml, p < 0.001) and MR fraction (− 17 ± 13% vs 
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1 ± 14%, p < 0.001). No signiicant change in LV ejection 
fraction (0.2 ± 8% vs 3 ± 9%, p = 0.15), RV ejection frac-
tion (2 ± 9% vs 1 ± 9%, p = 0.54) or LV mass (− 32 ± 19 g 
vs − 25 ± 18 g, p = 0.07) were seen between groups. Those 
with signiicant MR experienced a greater reduction in LV 
end-diastolic (p < 0.001) and end-systolic volumes (p = 0.04) 
when compared to the ‘non-signiicant’ MR group (Fig. 1).
Changes in MR fraction in the ‘signiicant MR’ group
In those with significant MR at baseline (n = 42), 77% 
(n = 32) had a signiicant reduction in MR, moving them 
into the ‘non-signiicant’ category at 6 months, with an 
overall reduction in MR fraction from 34 ± 6% to 17 ± 14% 
(p < 0.001) (Fig. 2).
Changes in haemodynamics and cardiac 
reverse remodeling according to MR ‘improver’ 
and ‘non‑improver’ status
From the total study population, MR signiicantly improved 
in 38% (n = 32) of patients 6-months post-TAVR, and 
worsened/unchanged in 62% (n = 53) of patients. At fol-
low up, the ‘improvers’ group, but not the ‘non-improvers’, 
had a signiicant improvement in LV stroke volume index 
(p = 0.04) and a greater increase in aortic forward flow 
(p < 0.001). Improvement in MR however was not associ-
ated with more favourable cardiac LV reverse remodeling 
compared with the ‘non-improvers’ (Fig. 3).
In the ‘improvers’ group, 72% (n = 23) had presence of 
LGE, 22% (n = 7) had no LGE and LGE imaging was not 
performed in 6% (n = 2) due to severe renal impairment. In 
those with LGE, the pattern of LGE was non-infarct pattern 
in 61% (n = 14), infarct pattern in 35% (n = 8), and mixed in 
4% (n = 1). The presence of LGE at baseline was associated 
with a greater reduction in MR fraction at 6-months follow-
ing TAVR intervention (− 11 ± 16% vs 0.2 ± 16%, p = 0.01).
Other factors associated with MR improvement
Univariate regression analysis was conducted to look for any 
clinical or CMR factors associated with MR reduction fol-
lowing TAVR. The following variables were tested: baseline 
demographics, baseline and 6 months- LV and RV ejection 
fraction, mass, and volumes; pre-treatment and post-treat-
ment mean trans-aortic gradient (see Online Supplementary 
Appendix). A higher baseline RV ejection fraction or RV 
stroke volume, and a greater reduction in LV end-diastolic 
Table 1  Baseline demographics 
in all patients, ‘non-signiicant’ 
and ‘signiicant’ MR groups
Data as mean ± SD, n (%)
AF atrial ibrillation, AV aortic valve, AVAi aortic valve area (indexed), CABG coronary artery bypass graft, 
CVA cerebrovascular attack, DM diabetes mellitus, HTN hypertension, MI myocardial infarction, PCI per-
cutaneous coronary intervention, PG pressure gradient, PHT pulmonary hypertension, PVD peripheral vas-
cular disease, STS society of thoracic surgery, TAVR transcatheter aortic valve replacement
All patients Non-signiicant MR 
(n = 43)
Signiicant MR 
(n = 42)
p value
Age at TAVR 80.2 ± 4.9 80.1 ± 7.2 80.2 ± 7.5 0.93
Male sex, n (%) 47 (55) 23 (53) 24 (57) 0.73
Logistic euroscore 19.8 ± 13.1 19.6 ± 13.1 20.0 ± 13.2 0.80
Euroscore II 5.45 ± 4.42 5.4 ± 4.4 5.5 ± 4.4 0.80
STS mortality 4.8 ± 2.97 5.1 ± 3.3 4.4 ± 2.5 0.20
STS morbidity 23.2 ± 8.42 23.7 ± 8.3 22.7 ± 8.5 0.50
HTN 44.7% 46.5% 42.8% 0.70
DM 20.0% 20.9% 19.0% 0.80
AF 21.2% 25.5% 16.6% 0.30
MI 22.4% 20.9% 23.8% 0.80
CABG 29.4% 20.9% 38.0% 0.08
PCI 25.9% 25.5% 26.1% 0.90
PVD 21.2% 23.2% 19.0% 0.60
CVA 15.3% 13.9% 16.6% 0.70
PHT 37.6% 30.2% 45.2% 0.15
Revascularization pre-TAVR 8 (9) 4 (9) 4 (10) 0.63
Aortic valve parameters (echocardiogram)
 AVAi 0.33 ± 0.84 0.33 ± 0.09 0.33 ± 0.07 0.99
 AV max velocity 4.7 ± 0.51 4.6 ± 0.51 4.8 ± 0.47 0.02
 AV mean PG 49.7 ± 11.6 47.5 ± 10.8 51.9 ± 12.1 0.07
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pressure (LVEDP) post-TAVR were all signiicantly associ-
ated with MR improvement. A lower aortic forward low 
at baseline was also associated with the reduction in MR. 
Multivariate predictors of improved MR following TAVR 
intervention were pre-operative absence of atrial ibrillation, 
a higher RV stroke volume and a lower aortic forward low 
at baseline.
Impact of MR on mortality
At a median of 3 (IQR 2.03–3.97) years follow-up, 24% 
(n = 20) of TAVR patients had died. MR severity at baseline 
did not difer between those who died and those who did not; 
(mortality rate 13% vs 14%, non-signiicant vs signiicant, 
p = 0.84) (Fig. 4). Those who died also had a comparable 
reduction in MR severity post-TAVR (− 7.3% vs − 8.3%, 
p = 0.81). Cumulative survival rates between the ‘improvers’ 
and ‘non-improvers’ did not difer at follow up (mean sur-
vival 5.5 years 95% CI 4.6–6.4 vs 5.5 years 95% CI 4.7–6.3, 
improvers vs non-improvers). Residual signiicant MR was 
also not associated with increased mortality.
Intra-observer variability for LV quantitation in this study 
was 1.6%, 3.6%, 3.0% and 1.8% for LV end-diastolic volume, 
LV mass, LV stroke volume and LV ejection fraction respec-
tively; whilst the coeicient of variation for peak aortic low 
velocity and aortic forward low volume was 0.2% and 1.7%.
Discussion
This is the irst CMR study to speciically assess MR in 
quantitative terms and evaluate its impact on cardiac reverse 
remodeling and mortality in patients undergoing TAVR. The 
main indings were (1) MR was shown to occur frequently 
in a TAVR population and those with ‘signiicant MR’ had a 
greater LV mass at baseline; (2) The presence of signiicant 
MR at baseline did not prevent LV reverse remodeling, as 
demonstrated by the substantial reduction in LV mass, LV 
diastolic and systolic volumes; (3) In those with signiicant 
MR at baseline, the MR is likely to improve following TAVR 
without the need for any speciic intervention on the mitral 
valve; (4) The presence of LGE at baseline was associated 
with a greater improvement in MR at 6-months post-TAVR; 
(5) Improvement in MR was neither associated with lower 
mortality nor more favourable cardiac reverse remodeling 
Table 2  Baseline CMR 
characteristics of patients in all 
patients, ‘non-signiicant’ and 
‘signiicant’ MR groups
Data as mean ± SD, n (%)
LA left atrial, LGE late gadolinium enhancement, LVEDV left ventricular end-diastolic volume, LVEF left 
ventricular ejection fraction, LVESV left ventricular end-systolic volume, LVSV left ventricular stroke vol-
ume, MR mitral regurgitation, RVEDV right ventricular end diastolic volume, RVEF right ventricular ejec-
tion fraction
All patients Non-signiicant 
MR (n = 43)
Signiicant MR (n = 42) p value
LV mass (g) 138.2 ± 35.3 127.5 ± 31 149 ± 32.9 0.007
LV mass index (g/m2) 76.1 ± 18.3 73.5 ± 16.5 83.3 ± 23.3 0.01
LVEDV (ml) 179 ± 49.3 170 ± 44.2 183 ± 45.3 0.33
LVESV (ml) 84.2 ± 43.5 86.7 ± 50.8 81.7 ± 34.9 0.59
LVEF (%) 54.8 ± 12.2 52.5 ± 13.3 56.3 ± 11 0.14
RVEDV (ml) 139.9 ± 36.0 135.6 ± 32.1 144.3 ± 39.5 0.27
RVEF (%) 54.2 ± 9.5 53.5 ± 10.7 55.0 ± 8.8 0.46
LA volume (ml) 131.8 ± 45.0 130.9 ± 51.4 132.8 ± 38.1 0.85
LA volume index (ml/m2) 72.8 ± 24.9 73.0 ± 28.8 72.6 ± 20.7 0.94
MR volume (ml) 22.4 ± 15.0 10.3 ± 8.1 34.5 ± 9.9 < 0.001
MR fraction (%) 22.6 ± 13.3 11.4 ± 9.0 34.2 ± 5.5 < 0.001
Classiications of LGE, n (%)
 None 24 (28) 15 (35) 9 (21)
 Infarct pattern 19 (22) 10 (23) 9 (21)
 Non-infarct pattern 33 (39) 14 (33) 19 (45)
 Mixed 4 (5) 2 (5) 2 (5)
 Not done 5 (6) 2 (5) 3 (7)
Presence of LGE n, (%)
 LGE present 56 (66) 15 (35) 9 (21) 0.188
 LGE absent 24 (28) 26 (60) 30 (71)
 LGE not done 5 (6) 2 (5) 3 (7)
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compared with the ‘non-improvers’; (6) Baseline MR sever-
ity was not associated with long-term mortality.
Our indings are consistent with other large echocardio-
graphic registries such as the Canadian Edwards SAPIEN 
registry [5], Italian CoreValve registry [14], and PART-
NER Trial Cohort A study [15] demonstrating that TAVR 
is associated with a signiicant amelioration in MR sever-
ity. Although some studies suggested that signiicant MR 
results in an increase in mortality rates after TAVR [5, 14, 
16, 17], the indings in our study are consistent with others 
[4, 7, 15, 18] which have not conirmed this association. 
Patients with a greater LV mass at baseline and higher aortic 
valve velocities (i.e. pressure-loaded ventricles) had a higher 
degree of MR in our study, likely due to raised LVEDP. We 
postulate that TAVR leads to the reduction of LVEDP and 
subsequently results in the amelioration of MR.
Interestingly, we found that improvement in MR was 
neither associated with more favourable cardiac reverse 
remodeling nor lower mortality rates compared with the 
‘non-improvers’. There is however the possibility that a 
6-month follow-up scan may have been too early to identify 
any diference in reverse remodeling between the groups. 
We also found that the presence of LGE at baseline was 
associated with improvement in MR 6-months post-TAVR. 
A possible explanation is that patients with signiicant MR 
tend to have a more critical AS and a higher trans-valvular 
gradient, which inevitably results in a higher LV mass and 
myocardial replacement fibrosis, depicted as LGE. The 
greater alleviation of ventricular afterload in these patients 
following TAVR could result in greater LV mass regression 
and systolic atrioventricular gradient, leading to a greater 
degree of MR reduction.
A key strength of our study was the use of CMR to relia-
bly quantitate MR volume with low intra- and inter-observer 
variabilities, irrespective of MR jet geometry [9, 19]. Previ-
ous TAVR studies have frequently used transthoracic echo-
cardiography for MR assessment, which has limited repro-
ducibility and relies on mathematical assumptions of LV 
geometry and cavity size, which may not apply in the remod-
eled ventricle. In fact, echocardiography, when compared 
to CMR, was found to overestimate MR severity in many 
patients [20]. Some studies have also suggested that CMR 
is more accurate than echocardiography in assessing the 
severity of MR, especially in those with prolapsing lealets 
and eccentric jets [21]. Echocardiographic evaluation of MR 
severity requires integration of various qualitative and quan-
titative measurements [22]. The variety of methods used for 
the quantitative assessment of MR may further explain the 
discrepancies amongst previous studies [5, 15–18].
The presence of myocardial ibrosis has been reported to 
be an adverse prognostic marker in patients with AS, with a 
6–8 fold increased mortality risk [23, 24]. Myocardial ibro-
sis has also been shown to adversely afect prognosis and 
functional outcomes following surgical aortic valve replace-
ment [13], but as yet its role is not fully elucidated in a 
TAVR population. In a small study (n = 20), the presence of 
LGE was found to predict higher cardiovascular mortality 
in patients with severe AS undergoing trans-femoral TAVR 
[25]. The clinical impact of LGE, however, has never been 
assessed in the setting of concomitant MR in severe AS. We 
have shown that the presence of LGE was associated with an 
improvement in MR in the short term (6 months) following 
TAVR, although the mechanism for this remains undeined.
Despite excellent procedural success and outcomes fol-
lowing TAVR, issues remain regarding optimal patient 
selection. Decision-making in patients with signiicant MR 
in the context of severe AS is often complex. One option is 
Table 3  CMR parameters pre- and post-TAVR interventions in all 
patients
Data as mean ± SD, n (%)
LA left atrial, LGE late gadolinium enhancement, LVEDV left ven-
tricular end-diastolic volume, LVEF left ventricular ejection fraction, 
LVESV left ventricular end-systolic volume, LVSV left ventricular 
stroke volume, MR mitral regurgitation, RVEF right ventricular ejec-
tion fraction, RVSV right ventricular stroke volume
All patients Baseline
n = 85
6 m follow up
n = 85
p value
LV mass (g) 138.2 ± 35.3 109.9 ± 31 < 0.001
LVEDV (ml) 179 ± 49.3 166.4 ± 44.2 < 0.001
LVESV (ml) 84.2 ± 43.5 75.7 ± 35.6 0.006
LVSV (ml) 94.5 ± 22.5 90.7 ± 18.7 0.04
LVEF (%) 54.8 ± 12.2 56.3 ± 10.6 0.10
RVSV (ml) 74.3 ± 18.4 78.7 ± 20.4 0.04
RVEF (%) 54.2 ± 9.5 55.4 ± 10.1 0.20
LA volume (ml) 131.8 ± 45.0 119.1 ± 41.3 < 0.001
MR volume (ml) 22.4 ± 15.0 13.7 ± 12.9 < 0.001
MR fraction (%) 22.6 ± 13.3 14.5 ± 12.4 < 0.001
MR classiications (n)
 Mitral regurgitation %
  MR none (0%) 8 14
  MR mild (5–15%) 20 35
  MR moderate (16–25%) 19 20
  MR moderate-severe 
(26–48%)
38 16 < 0.001
Classiications of LGE, n 
(%)
 None 24 (28) 28 (33)
 Infarct pattern 19 (22) 23 (27)
 Non-infarct pattern 33 (39) 24 (28) 0.23
 Mixed 4 (5) 3 (4)
 Not done 5 (6) 7 (8)
Presence of LGE, n (%)
 LGE present 56 (66) 50 (59)
 LGE absent 24 (28) 28 (33)
 LGE not done 5 (6) 7 (8)
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to perform a double valve (aortic and mitral) surgical proce-
dure, which might be considered too high-risk in this already 
high-risk population. The other option is to perform TAVR 
as a compromise solution, accepting non-treatment of con-
comitant MR with a potential negative impact on patient 
outcomes. Therefore, identifying patients with the highest 
and lowest likelihood for MR improvement could be very 
important in the clinical decision-making process. LGE-
CMR might allow clinicians to select patients who will most 
beneit from the TAVR procedure, obviating the need for 
high-risk double valve surgery. On the other hand, double-
valve surgery may be more appropriate in patients with a 
low likelihood of MR improvement after TAVR. Although 
our small sample size did not demonstrate mortality ben-
eits in those who improved their MR status, the literature to 
date has shown that MR improvement contributes to patient 
symptomatic improvement [26–28].
Limitations
The moderate sample size, short follow-up time frame 
and the single-centre study design limits the strength of 
our conclusions. However, comparisons between the two 
groups using the highly reproducible technique of CMR 
meant it was appropriately powered for LV reverse remod-
eling parameters. The exclusion of patients with pacemak-
ers (7%), severe AR and inclusion of survivors only in the 
CMR analysis raises the potential for selection bias. The 
analyzed population however did not difer in terms of base-
line characteristics from the original whole study popula-
tion. Because we excluded patients with contraindications to 
CMR and speciic medical conditions, our study population 
is highly selected and so our conclusions cannot be extrapo-
lated to all patients with severe AS.
Fig. 1  CMR characteristics 
at baseline and 6-months 
for ‘signiicant’ and ‘non-
signiicant’ MR groups. LVEDV 
left ventricular end-diastolic 
volume, LVESV left ventricular 
end-systolic volume, MR mitral 
regurgitation
Fig. 2  Change in MR fraction (%) in the ‘signiicant MR’ group 
post-TAVR. MR mitral regurgitant, TAVR transcatheter aortic valve 
replacement
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Additionally, our study had a high proportion of 
patients with atrial fibrillation (20%), an arrhythmia 
which could reduce the quality of image acquisition and 
therefore reduce the accuracy of volumetric quantiication 
with CMR. MR fraction in the context of severe AS may 
be overestimated using CMR phase contrast imaging due 
to underestimation of aortic forward low when sampling 
high velocities. When performing phase contrast-based 
low measurements in patients with heart valve replace-
ment, there is also a potential for low and volume miscal-
culation due to prosthesis-related distortions of the mag-
netic ield [29]. Confounders such as primary or ischemic 
etiology, change in medications and development of bun-
dle branch block or aortic regurgitation could additionally 
impact on cardiac reverse remodeling following TAVR. 
Finally, quantiication of ibrosis on LGE images were ana-
lyzed using a semi-automatic, signal intensity threshold 
method rather than the newer T1 mapping techniques, as 
the latter were not widely employed at the time of patient 
recruitment.
Conclusion
Signiicant MR is common in patients undergoing TAVR 
and improves in the majority post-procedure. Improvement 
in MR was not associated with LV reverse remodeling and 
baseline MR severity was not associated with mortality.
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